Disc Medicine, Inc. $IRON Shares Sold by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management reduced its Disc Medicine stake by 29.7% in the second quarter, selling 162,089 shares and retaining 384,158 shares worth approximately $28.1 million. Institutional investors collectively own 83.7% of IRON.
• Company insiders sold 110,712 shares valued at nearly $8.0 million over the past three months, including CEO John D. Quisel’s sale of 34,000 shares and Rahul Khara’s sale of 7,500 shares.
• Disc Medicine reported a quarterly loss of $1.54 per share, beating the $1.71 consensus estimate. Analysts maintain a Moderate Buy consensus with an average price target of $106, despite the stock trading at $77.44.

Assenagon Asset Management S.A. cut its position in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 29.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 384,158 shares of the company's stock after selling 162,089 shares during the quarter. Assenagon Asset Management S.A. owned approximately 1.01% of Disc Medicine worth $28,097,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of IRON. ANTIPODES PARTNERS Ltd acquired a new position in Disc Medicine in the fourth quarter valued at $33,000. KBC Group NV acquired a new position in shares of Disc Medicine during the 4th quarter valued at about $80,000. Persistent Asset Partners Ltd acquired a new position in shares of Disc Medicine during the 4th quarter valued at about $141,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Disc Medicine by 36.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company's stock worth $146,000 after acquiring an additional 490 shares during the period. Finally, Russell Investments Group Ltd. raised its stake in Disc Medicine by 15,137.5% during the third quarter. Russell Investments Group Ltd. now owns 2,438 shares of the company's stock worth $161,000 after purchasing an additional 2,422 shares during the period. Institutional investors and hedge funds own 83.70% of the company's stock.

Insider Buying and Selling

In other news, CEO John D. Quisel sold 34,000 shares of the business's stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $70.21, for a total transaction of $2,387,140.00. Following the sale, the chief executive officer directly owned 226,064 shares of the company's stock, valued at $15,871,953.44. The trade was a 13.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Rahul Khara sold 7,500 shares of the business's stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $70.22, for a total value of $526,650.00. Following the sale, the insider owned 52,173 shares in the company, valued at approximately $3,663,588.06. The trade was a 12.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 110,712 shares of company stock valued at $7,997,536 over the last three months. Company insiders own 3.76% of the company's stock.

Disc Medicine Price Performance

IRON stock opened at $77.44 on Monday. Disc Medicine, Inc. has a 52 week low of $40.00 and a 52 week high of $99.50. The company has a market capitalization of $2.96 billion, a price-to-earnings ratio of -11.77 and a beta of 1.00. The firm's 50-day moving average is $73.59 and its two-hundred day moving average is $69.78. The company has a current ratio of 24.14, a quick ratio of 24.14 and a debt-to-equity ratio of 0.09.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.71) by $0.17. On average, analysts forecast that Disc Medicine, Inc. will post -6.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

IRON has been the subject of a number of research reports. Wedbush reissued an "outperform" rating and set a $88.00 price target on shares of Disc Medicine in a research report on Wednesday, June 10th. Morgan Stanley increased their price objective on shares of Disc Medicine from $80.00 to $85.00 and gave the company an "overweight" rating in a research report on Monday, June 15th. Wall Street Zen raised Disc Medicine from a "sell" rating to a "hold" rating in a report on Saturday, August 1st. HC Wainwright upped their price objective on Disc Medicine from $118.00 to $120.00 and gave the company a "buy" rating in a research note on Thursday. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Disc Medicine in a report on Friday, July 17th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $106.00.

Disc Medicine News Summary

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: HC Wainwright raised its price target for Disc Medicine to $120 from $118 and maintained a Buy rating. The new target is well above recent trading levels and may support upside expectations. Price target article
• Positive Sentiment: HC Wainwright modestly improved its estimates for several periods, including FY2026 EPS to a loss of $6.64 from $6.72, Q4 2026 to a loss of $1.74 from $1.75 and FY2028 to a loss of $4.62 from $4.64. The revisions indicate slightly better expected results, although the company remains unprofitable. Earnings estimates article
• Neutral Sentiment: The analyst also lowered its FY2027 EPS forecast to a loss of $6.47 from $6.13 and trimmed its Q3 2026 estimate slightly to a loss of $1.71 from $1.70. Overall, the changes are limited and do not alter HC Wainwright’s Buy rating or $120 target.
• Negative Sentiment: Rosen Law Firm announced an ongoing investigation into potential securities claims alleging that Disc Medicine may have issued materially misleading information to investors. The announcement does not establish wrongdoing, but it adds legal and reputational uncertainty and could pressure the stock if additional claims or disclosures emerge. Rosen Law Firm investigation article
• Negative Sentiment: Insider Rahul Khara sold 5,000 shares for approximately $400,000, reducing his holdings by 8.72%. He continues to own a substantial position, so the sale may reflect portfolio or personal financial considerations, but it can still weigh on investor confidence. Insider selling article

Disc Medicine Profile

Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.

Want to see what other hedge funds are holding IRON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Disc Medicine, Inc. (NASDAQ:IRON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source